AU2013219242C1 - Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer - Google Patents
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancerInfo
- Publication number
- AU2013219242C1 AU2013219242C1 AU2013219242A AU2013219242A AU2013219242C1 AU 2013219242 C1 AU2013219242 C1 AU 2013219242C1 AU 2013219242 A AU2013219242 A AU 2013219242A AU 2013219242 A AU2013219242 A AU 2013219242A AU 2013219242 C1 AU2013219242 C1 AU 2013219242C1
- Authority
- AU
- Australia
- Prior art keywords
- methods
- naphthyridine
- pyrrolidinyl
- methylamino
- thiazolyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
Abstract Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4 dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-l-(2-thiazolyl)-1,8 naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013219242A AU2013219242C1 (en) | 2005-09-02 | 2013-08-23 | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
AU2016210657A AU2016210657A1 (en) | 2005-09-02 | 2016-08-03 | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/218,653 | 2005-09-02 | ||
US11/218,387 | 2005-09-02 | ||
US60/789,093 | 2006-04-03 | ||
US60/788,927 | 2006-04-03 | ||
US60/810,285 | 2006-06-01 | ||
AU2006287149A AU2006287149B2 (en) | 2005-09-02 | 2006-09-05 | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
AU2013219242A AU2013219242C1 (en) | 2005-09-02 | 2013-08-23 | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006287149A Division AU2006287149B2 (en) | 2005-09-02 | 2006-09-05 | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2016210657A Division AU2016210657A1 (en) | 2005-09-02 | 2016-08-03 | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2013219242A1 AU2013219242A1 (en) | 2013-09-12 |
AU2013219242B2 AU2013219242B2 (en) | 2016-05-19 |
AU2013219242C1 true AU2013219242C1 (en) | 2016-09-22 |
Family
ID=49115738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013219242A Ceased AU2013219242C1 (en) | 2005-09-02 | 2013-08-23 | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2013219242C1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817669A (en) * | 1994-06-14 | 1998-10-06 | Dainippon Pharmaceutical Co., Ltd. | Compounds, processes for the preparation thereof and anti-tumor agents |
-
2013
- 2013-08-23 AU AU2013219242A patent/AU2013219242C1/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817669A (en) * | 1994-06-14 | 1998-10-06 | Dainippon Pharmaceutical Co., Ltd. | Compounds, processes for the preparation thereof and anti-tumor agents |
Also Published As
Publication number | Publication date |
---|---|
AU2013219242A1 (en) | 2013-09-12 |
AU2013219242B2 (en) | 2016-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008016702A3 (en) | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic | |
WO2009075841A3 (en) | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders | |
IL248049A0 (en) | Sns-595 and methods of using the same | |
IL244727A0 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
WO2005105213A3 (en) | Indole and azaindole derivatives with antitumor action | |
WO2004103274A3 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
TW200640908A (en) | Chemical compounds | |
WO2007041637A3 (en) | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias | |
IL229136A0 (en) | Mek inhibitors and methods of their use | |
WO2007149406A3 (en) | Modified coagulation factor ix polypeptides and use thereof for treatment | |
MX2010003868A (en) | Chiral cis-imidazolines. | |
HK1075450A1 (en) | heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine | |
TW200510392A (en) | Chemical compounds | |
TW200505452A (en) | Chemical compounds | |
WO2005107467A3 (en) | Compositions including opioids and methods of their use in treating pain | |
MX2010004350A (en) | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylam ino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-c arboxylic acid in combination therapy. | |
NZ594829A (en) | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity | |
AU2013219242C1 (en) | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer | |
UA90264C2 (en) | Tri(cyclo) substituted amide compounds, pharmaceutical composition, methods for the treatment and prophylactic, process for the preparation of compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 MAY 2016 . |
|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 MAY 2016 |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |